EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change

Xiaojing Zheng, Ning Zhang, Lixia Wang, Hongjuan Zhao, ChengGang Liu, Jiayu Wang, Wanli Zhao, Junli Zhao, Peiyan Yang, Lorraina Robinson, Lindsay Hunt, Alex Lokken und 6 weitere

Journal of Neuropathology & Experimental Neurology · 06.08.2026

DOI: 10.1093/jnen/nlag085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, online erschienen am 06.08.2026. Verfasst von Xiaojing Zheng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, P.R. China. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Drug Discovery Foundation, Alzheimer’s Drug Discovery Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TDP-43 proteinopathies encompass frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), amyotrophic lateral sclerosis (ALS-TDP), and limbic predominant age related TDP-43 encephalopathy neuropathological change (LATE-NC). These proteinopathies exhibit subtype-specific aggregate architectures that may constrain epitope accessibility in situ. We compared a phosphorylation-independent monoclonal antibody targeting a C-terminal epitope (MAb No. 9) with the phospho-specific pSer409/410 antibody to determine whether its signal relates to regional neurodegeneration in a multicenter autopsy cohort spanning FTLD-TDP types A-C, ALS-TDP, and Alzheimer disease neuropathologic change (ADNC) with or without LATE-NC. Immunolabeling with MAb No. 9 detected pathological TDP-43 across all diagnostic groups with enhanced labeling of dystrophic neurites and thread/dot-like pathology in FTLD-TDP types A/B and in ALS-TDP. MAb No. 9 performance was equivalent to p409/410 in FTLD-TDP type C. In ADNC with stage 3 LATE-NC, MAb No. 9 revealed a greater limbic burden and labeled both α type and β type inclusions. Dual label immunofluorescence demonstrated strong spatial overlap with p409/410 but additionally highlighted fine punctate pathology. MAb No. 9 burden in FTLD-TDP type A correlated strongly with cortical neurodegeneration but showed weaker and variable associations, particularly in severely atrophic cortex. These findings indicate that filament architecture governs C-terminal epitope accessibility and that MAb No. 9 may be a complementary tool for subtype refinement, clinicopathologic correlation and translational biomarker development in TDP-43 proteinopathies.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer disease neuropathologic changeTDP-43frontotemporal lobar degenerationlimbic-predominant age-related TDP-43 encephalopathy neuropathological changephosphorylation-dependent antibodyphosphorylation-independent antibodyproteinopathy

Autor:innen und Institutionen

  • Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, P.R. China.
  • Department of Pathology, University of Utah, Salt Lake City, UT, United States.
  • Department of Pathology, University of Kentucky, Lexington, KY, United States.
  • Department of Pathology, University of Pittsburgh, Pittsburgh, PA, United States.
  • Epigenomics and Computational Biology Lab, Fralin Life Sciences Institute, Virginia Tech, Blacksburg, VA, United States.

ORCID-Profile: Qinwen Mao

Förderung

  • NIA NIH HHS
  • Alzheimer's Drug Discovery Foundation
  • Alzheimer’s Drug Discovery Foundation
  • National Institute on Aging

Zitieren

APA

Zheng, X., Zhang, N., Wang, L., Zhao, H., Liu, C., Wang, J., Zhao, W., Zhao, J., Yang, P., Robinson, L., Hunt, L., Lokken, A., Lin, L., Nelson, P. T., Kofler, J., Xie, H., Xia, H., & Mao, Q. (2026). A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlag085

Vancouver

Zheng X, Zhang N, Wang L, Zhao H, Liu C, Wang J, et al. A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change. Journal of Neuropathology & Experimental Neurology. 2026. doi:10.1093/jnen/nlag085

BibTeX
@article{Zheng2026,
  author = {Zheng, Xiaojing and Zhang, Ning and Wang, Lixia and Zhao, Hongjuan and Liu, ChengGang and Wang, Jiayu and Zhao, Wanli and Zhao, Junli and Yang, Peiyan and Robinson, Lorraina and Hunt, Lindsay and Lokken, Alex and Lin, Leo and Nelson, Peter T and Kofler, Julia and Xie, Hehuang and Xia, Haibin and Mao, Qinwen},
  title = {A phosphorylation‑independent monoclonal antibody improves detection of TDP‑43 pathology across frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and limbic predominant age related TDP‑43 encephalopathy neuropathological change},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2026},
  doi = {10.1093/jnen/nlag085}
}
Kostenlos starten →